A cancer drug newly approved by the FDA could help thousands of people every year and it's already giving hope to a family who thought they were out of options for their 9-year-old son. At age 5, Ashton Leeds was diagnosed with stage 4 thyroid cancer. After his cancer became resistant to treatment, Ashton joined a trial for a cutting-edge drug called larotrectinib that targets a specific genetic mutation found in certain kinds of cancers.
The National Cancer Institute announced funding totaling $4 million for new adult and pediatric brain cancer research projects. Project HOPE (High-Grade Glioma-Omics in Pediatric and AYA) will use single-cell sequencing approaches designed to capture critical information on tumor cell types and the tumor microenvironment that are missed by traditional sequencing techniques.